- Home
- PRAX vs ULCC Comparison
PRAX vs ULCC Comparison
Compare PRAX & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- ULCC
- Stock Information
- Founded
- PRAX 2015
- ULCC 1994
- Country
- PRAX United States
- ULCC United States
- Employees
- PRAX N/A
- ULCC N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- PRAX Health Care
- ULCC Consumer Discretionary
- Exchange
- PRAX Nasdaq
- ULCC Nasdaq
- Market Cap
- PRAX 599.7M
- ULCC 719.5M
- IPO Year
- PRAX 2020
- ULCC 2021
- Fundamental
- Price
- PRAX $42.34
- ULCC $3.38
- Analyst Decision
- PRAX Strong Buy
- ULCC Hold
- Analyst Count
- PRAX 11
- ULCC 11
- Target Price
- PRAX $114.73
- ULCC $5.56
- AVG Volume (30 Days)
- PRAX 279.7K
- ULCC 3.4M
- Earning Date
- PRAX 08-12-2025
- ULCC 08-07-2025
- Dividend Yield
- PRAX N/A
- ULCC N/A
- EPS Growth
- PRAX N/A
- ULCC N/A
- EPS
- PRAX N/A
- ULCC 0.30
- Revenue
- PRAX $8,122,000.00
- ULCC $3,822,000,000.00
- Revenue This Year
- PRAX N/A
- ULCC $5.01
- Revenue Next Year
- PRAX $6,358.50
- ULCC $13.85
- P/E Ratio
- PRAX N/A
- ULCC $11.44
- Revenue Growth
- PRAX 270.02
- ULCC 5.99
- 52 Week Low
- PRAX $26.70
- ULCC $2.79
- 52 Week High
- PRAX $91.83
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- PRAX 54.36
- ULCC 37.82
- Support Level
- PRAX $41.64
- ULCC $3.33
- Resistance Level
- PRAX $44.99
- ULCC $3.71
- Average True Range (ATR)
- PRAX 2.55
- ULCC 0.20
- MACD
- PRAX -0.11
- ULCC -0.07
- Stochastic Oscillator
- PRAX 51.07
- ULCC 5.71
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.